Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7529781 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL18244192 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL112495 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL7533356 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL7532471 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL7529787 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL2053848 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL16258755 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL7530266 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 | |
| SCHEMBL2053850 | 1.00 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347757-A1 | FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING | Givaudan SA (CH) | 2024-04-10 | — | — | EP | claimed |
| WO-2022234149-A1 | FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING | GIVAUDAN SA (CH) | 2022-11-10 | — | — | WO | claimed |
| US-9796945-B2 | Perfume compositions | JOHNSON & JOHNSON CONSUMER INC. (US) | 2017-10-24 | — | — | US | claimed |
| WO-2006102777-A1 | SKIN LIGHTENING METHODS, COMPOSITIONS AND PRODUCTS | GIVAUDAN SA (CH) | 2006-10-05 | — | — | WO | claimed |
| EP-0983989-B1 | Methylcyclotetradec-5-ene-1-one | GIVAUDAN SA (CH) | 2002-03-27 | — | — | EP | claimed |
| US-6326349-B1 | MUSK ODOR | GIVAUDAN ROURE (INTERNATIONAL) SA (CH) | 2001-12-04 | — | — | US | claimed |
| EP-0983989-A1 | Methylcyclotetradec-5-ene-1-one | Givaudan Roure (International) S.A. (CH) | 2000-03-08 | — | — | EP | claimed |
| EP-3947334-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-10-29 | — | — | EP | disclosed |
| CN-119698458-A | Improvements in or relating to organic compounds improvements relating to organic compounds | 诺维信公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024213536-A1 | FRAGRANCE COMPOSITION | GIVAUDAN SA (CH) | 2024-10-17 | — | — | WO | disclosed |
| US-20240192184-A1 | DETECTION OF FLAVOUR LOSS | GIVAUDAN SA (CH) | 2024-06-13 | — | — | US | disclosed |
| EP-4347757-A1 | FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING | Givaudan SA (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-11820961-B2 | Musk compositions and methods of use thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-11-21 | — | — | US | disclosed |
| WO-2008116338-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008113495-A2 | PERFUME COMPOSITIONS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-09-25 | — | — | WO | disclosed |
| WO-2006102777-A1 | SKIN LIGHTENING METHODS, COMPOSITIONS AND PRODUCTS | GIVAUDAN SA (CH) | 2006-10-05 | — | — | WO | disclosed |
| EP-0983989-B1 | Methylcyclotetradec-5-ene-1-one | GIVAUDAN SA (CH) | 2002-03-27 | — | — | EP | disclosed |
| US-6326349-B1 | MUSK ODOR | GIVAUDAN ROURE (INTERNATIONAL) SA (CH) | 2001-12-04 | — | — | US | disclosed |
| JP-2000178223-A | METHYLCYCLOTETRADECA-5-EN-1-ONES | GIVAUDAN ROURE INTERNATL SA | 2000-06-27 | — | — | JP | disclosed |
| EP-0983989-A1 | Methylcyclotetradec-5-ene-1-one | Givaudan Roure (International) S.A. (CH) | 2000-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820961-B2 | Musk compositions and methods of use thereof | MUSK, MSI2, SYMPK | TRIM24 1652/4885TRIM33 2614/4885ALDH1A1 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.